CCNY–MSK Cancer Partnership for Patient Education and Community Outreach
2/2 CCNY-MSKCC Partnership for Cancer Research, Education and Community Outreach
This partnership develops new ways to reduce immunotherapy side effects, create targeted cancer drugs, and improve communication and genetic testing for people with cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11194497 on NIH RePORTER |
What this research studies
This cross-institution partnership brings Memorial Sloan Kettering and City College researchers together to move discoveries quickly from the lab to patients and communities. Projects include testing a program to reduce side effects and missed appointments for people on immune checkpoint inhibitors, using chemistry and cell studies to find small molecules that can block cancer-driving transcription factors, studying AI-based medical interpretation tools to improve cancer care for non-English speakers, and identifying inherited factors that shape tumor genomes in lung cancer. The work combines clinical studies, lab-based drug discovery, genetic analyses, and community-engaged outreach in New York-area clinics.
Who could benefit from this research
Good fit: Ideal participants include people receiving immune checkpoint inhibitor therapy, patients with lung cancer, and individuals who need medical interpretation during cancer care at participating centers.
Not a fit: Patients with cancer types not targeted by these projects or those who do not receive care at the participating institutions are less likely to benefit directly from this partnership.
Why it matters
Potential benefit: If successful, the work could reduce treatment side effects, lead to more targeted drugs, improve doctor–patient communication, and enable more personalized care for lung cancer.
How similar studies have performed: Some aspects build on prior successes in managing immunotherapy side effects and genetic studies of tumors, while small-molecule targeting of transcription factors and AI medical interpreting are newer and less established.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Gany, Francesca M — Sloan-Kettering Inst Can Research
- Study coordinator: Gany, Francesca M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.